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Abstract
Background: Human cytomegalovirus (HCMV) is a ubiquitous pathogen that causes serious problems in
immunocompromised or immunologically immature hosts. Vaccination is the preferred approach for prevention of
HCMV infection, but so far no approved HCMV vaccine is available. In this study, we assessed the immunogenicity
and protective immunity of a formalin-inactivated murine cytomegalovirus vaccine (FI-MCMV) in a mouse model in
combination with adjuvants MF59, alum, or chitosan.
Methods: Specific-pathogen-free BALB/c mice aged 6–8 weeks were immunized twice, 3 weeks apart, with various
doses of FI-MCMV (0.25 μg, 1 μg, 4 μg) with or without adjuvant. Mice were challenged with a lethal dose (5 × LD50) of a
more virulent mouse salivary gland-passaged MCMV 3 weeks after the second immunization. The protective immunity of
the vaccine was evaluated by determining the survival rates, residual spleen and salivary gland viral loads, body weight
changes, and serum anti-MCMV IgG titers.
Results: Immunization with FI-MCMV vaccine induced a high level of specific antibody response. Antigen sparing was
achieved by the addition of an adjuvant, which significantly enhanced the humoral response to vaccine antigens with a
wide range of doses. The level of live virus detected in the spleen on day 5 and in the salivary glands on day 21 after the
lethal challenge was significantly lower in adjuvant-treated groups than in controls. Survival rates in adjuvant-treated
groups also increased significantly. Furthermore, these protective immune responses were sustained for at least 6 months
following immunization.
Conclusions: These results show that inactivated MCMV vaccine is effective, and that the adjuvanted FI-MCMV vaccine
provides more effective and longer-term protection than the adjuvant-free vaccine.
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Background
Human cytomegalovirus (HCMV), a member of the Beta-
herpesvirinae subfamily (type 5), is a ubiquitous pathogen
that infects approximately 50–100% of the adult popu-
lation worldwide, depending upon both socioeconomic
factors and geographic location [1,2]. Cytomegalovirus
is characterized by strict species specificity and a life-
long latency in the host [1]. Humans are the only reser-
voir of HCMV. In immunocompetent populations, the
majority of HCMV infections present as asymptomatic
or latent infections, but several high-risk groups, such
as neonates, solid organ or allogeneic stem-cell trans-
plant recipients, and HIV-infected patients, are suscep-
tible to HCMV infection and may develop serious
disease [3,4]. HCMV is the most common infectious
cause of mental retardation and other birth defects in
children, and causes extreme morbidity and mortality
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in congenitally infected newborns [5,6]. HCMV is also
regarded as the most dangerous viral pathogen affecting
transplantation. Therefore, CMV infection is indeed a
serious public health problem [7,8].
Presently there is no suitable treatment for HCMV
infection [9]. Therefore, effective prevention against this
important pathogen is clearly desirable. The develop-
ment of a vaccine to prevent HCMV infection has been
assigned the highest priority by the US Institute of
Medicine [7,10], but an approved HCMV vaccine is not
yet available. Several candidate vaccines have been tested
in clinical studies [11], including those based on live
attenuated CMV, protein subunits, recombinant vectors,
DNA, and peptides [4,10]. However, none of the experi-
mental HCMV vaccines showed the desired protective
efficacy in phase 3 clinical trials [2].
In the current study, we investigated the immunogen-
icity and protective efficacy of an inactivated CMV
vaccine. Because of the strict species specificity of CMV
infection, there is no animal model available for direct
study of HCMV mechanisms employed during infection
and immunity. Murine cytomegalovirus (MCMV) infec-
tion is the most widely used animal model simulating
HCMV infection [12,13]. We therefore used a mouse
model of lethal MCMV infection to study the immune
response to an inactivated MCMV vaccine.
Adjuvants are non-specific immune-enhancing sub-
stances, of which there are multiple types. Currently,
alum is the only adjuvant permitted for human use in
the USA. Meanwhile many other adjuvants are being
studied in animal experiments and human clinical trials
[14-16], of which adjuvant MF59, an oil-in-water emul-
sion, has been shown to exhibit a safe and highly effect-
ive adjuvant activity. MF59 is a component of the flu
vaccine FLUAD™, which has been used clinically in over
20 European countries [17]. Chitosan is a non-toxic, bio-
logically tolerant and biodegradable natural polysacchar-
ide isolated from exoskeletons of crustaceans or insects
[18,19]. We designed our study to examine the protect-
ive effect of a vaccine with these three adjuvants.
Methods
Viruses and mice
We used the MCMV Smith strain and propagated the
virus in NIH 3T3 cells. The MCMV derived from cell
culture propagation is referred to as “TC-MCMV” (tis-
sue culture-derived MCMV) [20]. The MCMV isolated
from mouse salivary glands (SG) followed by in vivo
passage for virulence enhancement is referred to as “SG-
MCMV”, and was used in our lethal challenge experi-
ments. High-virulence SG-MCMV was prepared from
10 in vivo passages. Passage-10 SG-MCMV stock had
a titer on 3T3 cells of 107.1 PFU/ml and a 50% lethal
dose (LD50) of approximately 10
5 PFU virus particles in
BALB/c mice. Lethal challenge was performed with 5 ×
LD50 virus stock.
Specific-pathogen-free (SPF) female BALB/c mice, 6–8
weeks old, were purchased from the Center for Disease
Control and Prevention in Hubei Province, China. They
were bred in the Animal Resource Center at the Wuhan
Institute of Virology, Chinese Academy of Sciences. All
mice were maintained in SPF conditions. All procedures
were reviewed and approved by the Animal Care Com-
mittee of Wuhan Institute of Virology.
Preparation of inactivated vaccine and adjuvants
Inactivated vaccine was prepared with tissue culture-
derived extracellular MCMV. Briefly, 3T3 cells were in-
fected by MCMV and incubated at 37°C for 4–5 days.
When the monolayer exhibited 100% cytopathic effect, the
medium from the infected cells was harvested and the cell
debris removed by centrifugation at 6,500 × g at 4°C for
20 min. The total volume of crude virus stock was quanti-
fied and inactivated by mixing with 37% formalin at a
1/4000 ratio, as described previously [21,22], except that
inactivation was maintained at 4°C for 1 week with stirring.
To confirm the absence of detectable infectivity, 100 μl of
formalin-treated virus was used to infect the 3T3 cells. The
3T3 cells were incubated for 7 days, and no cytopathic ef-
fect was observed. Post-inactivation virus stock was pelleted
and purified by ultracentrifugation, as described previously
[12,23]. The resulting preparation was confirmed to be
completely inactivated by plaque assay and intraperitoneal
infection of BALB/c mice, in which we did not detect virus
from the spleens, livers, and salivary glands of the mice.
Mock formalin-inactivated (FI)-MCMV vaccine was pre-
pared from the supernatants of uninfected NIH 3T3 cells
and formalin treated as described above. The protein con-
tent of the inactivated whole-virion vaccine was determined
with a Pierce BCA Protein Assay kit (Pierce, Rockford, IL),
using BSA as a standard.
The adjuvants used were MF59, alum, and chitosan.
MF59 is a submicron oil-in-water emulsion adjuvant,
and its components include 5% squalene, 0.5% Tween
80, and 0.5% Span 85 (Sigma, St Louis, MO). Aluminum
hydroxide (National Vaccine & Serum Institute, China)
was added to the antigen solution to a final concentra-
tion of 0.5 μg/μl. Chitosan (Sigma) at a concentration of
0.2% (w/v) was diluted in a 25 mM sodium acetate solu-
tion (pH 5.0). The chitosan was prepared by: adding
0.04 g chitosan to 20 ml of a 0.1 M solution of glacial
acetic acid [concentration 0.2% (w/v)], mixing it for
about an hour to dissolve it, adjusting its pH with
NaOH, and sterilizing it by filtration through a 0.45 μm
filter. The final concentration of chitosan used for
immunization was 50 μg/ml. The adjuvant and antigen
were mixed and maintained at 4°C for 1 h and shaken to
produce a homogenous mixture.
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Immunization of the mice
Each experimental group had 10 mice. The inactivated
vaccines, at doses of 4 μg, 1 μg, and 0.25 μg with or without
an adjuvant (MF59, alum, or chitosan), were prepared for
immunization by intraperitoneal (i.p.) injection. Immuniza-
tions were performed twice, 3 weeks apart. The volume of
each dose was 200 μl. The adjuvant-only group of mice was
administered with MF59, alum, or chitosan only and the
control group of mice received PBS. In addition, one group
of mice was immunized with formalin-treated mock virus
preparation (Mock). To test whether the FI-MCMV vaccine
could provide long-term protection, immunizations were
performed with 4 μg FI-MCMV and adjuvants, three times
by i.p. injection.
To determine whether different immunization routes
could provide similar protection, another experiment
was performed as described above, except that the mice
were immunized by intramuscular (i.m.) injection.
Virus challenge
For lethal dose experiments, the more virulent
passage-10 SG-MCMV was used. At 3 weeks after the
second immunization, or 6 months after the third
immunization, mice were challenged with a lethal dose
(5 × LD50, 200 μl/mouse) of SG-MCMV by i.p. injection.
This infection could cause systemic virus replication in
mice and death of all unimmunized mice within 4–7 days
after the infection. During the 3 weeks following virus
challenge, body weight was recorded daily until death
occurred.
Detection of MCMV-specific antibody
Mouse serum samples were collected 3 weeks after the first
and second immunizations. Serum samples were stored
at -20°C. Anti-MCMV serum IgG titers were determined by
enzyme-linked immunosorbent assay (ELISA). ELISA was
performed in a 96-well polystyrene microtiter plate follow-
ing standard protocols. Briefly, inactivated MCMV vaccine
was added, followed by serial two-fold dilutions of sera from
each group of mice and then biotin-conjugated goat anti-
mouse IgG Ab (γ-chain specific) (Southern Biotechnology
Associates, Birmingham, AL). Streptavidin conjugated with
alkaline phosphatase (Southern Biotechnology Associates)
was then added, followed by p-nitrophenyl-phosphate.
Chromogen production was measured based on absorbance
at 414 nm and 405 nm in an ELISA reader (Labsystems
Multiskan Ascent Autoreader, Finland). Ab-positive cutoff
values were set as mean + 2SD of unimmunized control
sera. The ELISA Ab titer was expressed as the highest
serum dilution to produce a positive reaction.
Collection of samples
Five days after the virus challenge, four mice from each
group were sacrificed and the spleens taken aseptically
for detection of virus titer. The six remaining mice of
each group were monitored for weight loss and sur-
vival. On day 21 post-challenge, when survival observa-
tions were complete, four mice were taken randomly
from the remaining six mice for aseptic collection of
salivary glands and the viral load was determined.
Determination of the virus titer in infected organs
Spleens and salivary glands were homogenized in 1:10
(w/v) volume with minimal essential media containing 10%
calf serum. The homogenized fluids were centrifuged and
the supernatants stored in aliquots at -80°C.
Viral loads were determined using a plaque-forming
cell assay. Briefly, organ homogenates were 10-fold
serially diluted, and each dilution was used to infect the
3T3 cells cultured in 48-well plates. Infections were
performed in triplicate and to each well was added viral
dilution to 100 μl. After 1 h of absorption, supernatant
was aspirated and 0.5 ml viscous medium was added to
each well. After incubation for 4–6 days, viral plaques
were counted and the viral PFU per milliliter were
calculated. The virus titer for each experimental
group was presented as the mean of mouse samples
in that group ± SD.
Statistical analysis
The experimental results were evaluated by One-Way
ANOVA (SPSS 17.0 software for Windows). Test of
homogeneity-of-variance followed by One-Way ANOVA
with LSD post-hoc tests were used to test for differences
among the same dose groups. If the p-value was less
than 0.05, the difference was considered significant. The
significance of the differences in survival rates between
the experimental and control groups was determined
using Fisher’s exact test.
Results
Antibody responses induced by FI-MCMV vaccine of
various formulations
Preliminary experiments showed that immunizing mice
intraperitoneally with 4 μg FI-MCMV vaccine three
times protected mice against a lethal challenge of SG-
MCMV, whereas two immunizations did not provide
protection (data not shown). Based on these results, we
sought to enhance vaccine effectiveness by using adju-
vants. We used three doses (0.25 μg, 1 μg, and 4 μg) of
FI-MCMV vaccine with or without an adjuvant (MF59,
alum, or chitosan), with a booster shot 3 weeks after
priming. Blood was taken 3 weeks after the first and
second immunizations, and ELISA was used to deter-
mine serum anti-MCMV IgG titers (Table 1).
The FI-MCMV vaccine had good immunogenicity
and was able to induce a humoral immune response.
Antibody titers after the immunization boost were
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higher than those after priming. IgG antibody levels
correlated positively with the vaccine dose. The anti-
body titer was greater and the elicited immune re-
sponse stronger with a higher vaccine dose. When
the vaccines were formulated with an adjuvant, the
antibody levels increased significantly compared with
adjuvant-free vaccines. No anti-MCMV IgG was de-
tected in MF59, alum, and chitosan alone or in mock
vaccine-treated mice, which suggested that neither the
adjuvant-only treatment nor the Mock vaccine could
induce specific anti-MCMV immune responses.
Antibody titers in the alum-adjuvanted group were
about 10 times higher than those in the corresponding
vaccine-only groups. Antibody titers in the chitosan
group were close to those in the alum group. Interest-
ingly, MF59-adjuvanted groups had the best antibody
response. These results suggest that MF59 is a more
effective adjuvant than alum and is capable of signifi-
cantly enhancing the humoral immune response.
Protection provided by immunization with FI-MCMV
vaccine alone or with adjuvants against lethal virus
challenge
Mice were immunized twice, with a 3-week interval,
with FI-MCMV alone or with adjuvants. Three weeks
after the boost, mice were challenged with a lethal dose
of SG-MCMV (5 × LD50). Table 2 shows the survival
rates for all the experimental groups.
All mice in the control group (including mock
vaccine) and adjuvant-alone treatment groups died
within 8 days after a lethal challenge with SG-MCMV.
Immunization with FI-MCMV vaccine (no adjuvant) at
all three doses did not provide sufficient protection, but
immunization with adjuvanted FI-MCMV significantly
improved protection. At a low dose (0.25 μg), the sur-
vival rate in the FI-MCMV plus MF59 group reached
83.3%, while mice immunized with FI-MCMV plus alum
or chitosan were not protected. At the 1 μg dose, all
mice in the FI-MCMV plus MF59 group survived, while
Table 1 Antibody titers in sera of mice immunized with various doses of FI-MCMV with or without adjuvant by i.p.
injection and viral loads in mouse organs after lethal viral challengea
Immunogen FI-MCMV ELISA titer (2n) of IgG antibodyb Spleen virus titers
(log10 PFU/ml)
Salivary gland virus
titers (log10 PFU/ml)Dosage (μg) Immunization once Immunization twice
Adjuvant-free 0.25 3.33 ± 0.58 5.67 ± 0.52 5.16 ± 0.22 Not donef
+ Chitosan 5.83 ± 1.17c 9.83 ± 1.17c 5.12 ± 0.28e Not done
+ Alum 6.67 ± 1.63c 11.17 ± 0.98c 5.06 ± 0.21e Not done
+ MF59 7.50 ± 1.52c 12.83 ± 1.47c,d 4.06 ± 0.62c,d,e 4.76 ± 0.48
Adjuvant-free 1 5.33 ± 0.58 9.17 ± 0.98 5.03 ± 0.40e Not done
+ Chitosan 6.67 ± 1.15 12.67 ± 1.03c 4.83 ± 0.12e 5.46 ± 0.57
+ Alum 7.83 ± 0.98c 14.00 ± 0.63c 4.31 ± 0.83e 5.12 ± 0.91
+ MF59 11.33 ± 0.82c,d 15.33 ± 1.03c,d 3.45 ± 0.56c,e 4.34 ± 0.42
Adjuvant-free 4 8.67 ± 0.82 11.67 ± 1.03 4.85 ± 0.21e 5.70 ± 0.38
+ Chitosan 10.50 ± 0.55c 14.83 ± 1.17c 3.95 ± 0.48c,e 4.57 ± 0.74c
+ Alum 11.00 ± 0.89c 15.17 ± 0.41c 3.61 ± 0.66c,e 4.10 ± 0.27c
+ MF59 12.17 ± 0.75c 17.00 ± 1.10c,d 2.08 ± 0.81c,d,e 2.31 ± 0.43c,d
Chitosan only - Undetected Undetected 5.76 ± 0.29 Not done
Alum only Undetected Undetected 5.83 ± 0.38 Not done
MF59 only Undetected Undetected 5.74 ± 0.18 Not done
Mock Undetected Undetected 5.61 ± 0.36 Not done
PBS - - 5.94 ± 0.25 Not done
aThe mice were immunized by i.p. injection twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or
chitosan). Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Mice were challenged with a lethal
dose of SG-MCMV 3 weeks after the boost. Spleen virus titers 5 days later and salivary gland virus titers 3 weeks after the challenge were measured. Results are
expressed as means ± standard deviation of tested mice in each group.
bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
eSignificant difference (p < 0.05), compared with control subjects.
fViral titer measurement was not performed because of the mouse death before the day 21 post-infection.
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mice in the alum- or chitosan-adjuvanted groups were
not completely protected. At the 4 μg dose, all three
adjuvanted groups had full protection. These results
indicated that immunizing twice with adjuvanted
FI-MCMV vaccine could achieve excellent protection.
Infectious viral loads in mouse spleen and salivary glands
after lethal challenge
The spleen is a key organ of virus invasion and replica-
tion at the acute phase of SG-MCMV infection, and viral
load in the spleen decreases rapidly after the acute
phase. The salivary gland is another important organ for
CMV infection, latency, and dissemination. The capacity
of vaccine-induced protective immunity to eradicate
infected viruses in vivo may be directly reflected by the
titers of infectious viruses in the spleen and salivary
glands. Spleen and salivary gland samples were collected
on days 5 and 21 after the lethal challenge, respectively.
As shown in Table 1, the titers of virus in the spleen
for the control mice after challenge reached 105.94 PFU/
ml, whereas the titers in the spleen following vaccination
decreased greatly. Addition of an adjuvant (MF59, alum,
or chitosan) to vaccines reduced the virus titers in the
spleen. The MF59-adjuvanted groups had significantly
lower titers than the vaccine-only group for all three
doses, while the alum- and chitosan-adjuvanted groups
had significantly lower titers, though only for the 4 μg
dose, than the vaccine-only group. These results clearly
show that immune responses induced by adjuvanted-
inactivated vaccine can effectively eradicate infectious
virus from the spleen. The most dramatic difference was
observed in the MF59-adjuvanted 4 μg vaccine group,
where the virus titer decreased more than 7000-fold
relative to controls.
Salivary gland viral loads were determined only on surviv-
ing mice since mice with no or little protection died. Mice
immunized with adjuvanted vaccine had lower salivary
gland titers than mice in the vaccine-only group (Table 1).
Moreover, the MF59-adjuvanted 4 μg vaccine group had
significantly lower titers than the corresponding alum- or
chitosan-adjuvanted groups. The salivary gland is widely
believed to be the most important organ for CMV latency
and dissemination. Therefore, a significantly lower salivary
gland viral load is an important indicator of the protective
effect of a vaccine.
Signs of infection and body weight change in mice after
lethal challenge
The challenge experiment found that morbidity was
observed at day 2 after the challenge, and within a week,
obvious weight losses were observed in unprotected
mice. The main signs of infection included lethargy,
piloerection, hunched posture, and emaciation. Unpro-
tected mice typically died within 4–8 days of infection.
In contrast, mice with protective immunity usually
started to recover gradually after 1 week and did not
present with visible signs of infection for up to 2 weeks
after infection.
The body weight changes were observed for 21 days
after the challenge (Figure 1). Weight loss was most
marked by day 5, and the largest weight loss in the con-
trol group was close to 30%. In contrast, body weight
loss in all immunized groups was relatively reduced, in-
dicating protection provided by vaccination. The weight
loss in the 4 μg dose groups was lower than that in the
mice given 1 μg and 0.25 μg doses. Mice immunized
with adjuvanted vaccines showed apparently more subtle
signs of infection and smaller weight loss ratios, and
their body weight recovery was faster than the vaccine-
only groups.
When the three adjuvants were compared for protection
against the challenge, MF59 showed superior results
relative to alum and chitosan. However, 4 μg FI-MCMV
produced full protection in all three adjuvanted groups,
although morbidity differed among mice in these groups.
Mice immunized with 4 μg and 1 μg doses of MF59-
adjuvanted vaccine showed little signs of infection, and the
4 μg FI-MCMV/MF59 showed almost no weight loss.
Table 2 Survival after lethal SG-MCMV challenge in mice immunized intraperitoneally with various doses of inactivated
vaccine with or without adjuvanta
Immunogen Protection against SGV challenge (Survival mice/total mice) by various doses of FI-MCMV immunization
- 0.25 μg 1 μg 4 μg
Adjuvant-free 0/6 0/6 0/6 2/6
+ Chitosan 0/6 0/6 2/6 6/6*
+ Alum 0/6 0/6 4/6 6/6*
+ MF59 0/6 5/6* 6/6* 6/6*
Mock 0/6 - - -
PBS 0/6 - - -
aThe mice were immunized twice, 3 weeks apart, with various doses (0.25, 1, or 4 μg) of the vaccine with or without adjuvant (MF59, alum, or chitosan) by i.p.
injection. The mice were challenged with a lethal dose of SG-MCMV 3 weeks after the second immunization. Mouse survival 3 weeks after challenge
was measured.
*Significant difference (p < 0.05), compared with control subjects.
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In contrast, mice immunized with alum- or chitosan-
adjuvanted vaccine, with even the highest dose, had appar-
ent signs of infection within 1 week of challenge combined
with evident weight loss.
Immunization of mice with adjuvanted FI-MCMV could
provide long-term protection against lethal challenge
To determine whether immunization with FI-MCMV
could provide long-term protection for mice, we immu-
nized mice by i.p. injection with 4 μg FI-MCMV vaccine
with or without an adjuvant (MF59, alum, or chitosan)
three times at 3-week intervals. Six months after the
third immunization, the mice were challenged with a le-
thal dose of SG-MCMV, and the survival rates observed
for 3 weeks (Table 3).
Control mice started to die at day 3 post-challenge,
and by day 6 only 1/15 mice was still alive. The survival
rate of mice immunized with 4 μg FI-MCMV alone was
21.4%—a sharp contrast to the full protection provided
by three immunizations observed in preliminary experi-
ments. This suggested that protective immunity grad-
ually declined with time, which was consistent with pre-
challenge serum anti-MCMV IgG titers. Antibody levels
at 6 months declined for immunized groups, to various
degrees, although antibody levels in the three adjuvanted
groups remained at levels significantly higher than those
in the vaccine-only groups (Table 3).
The long-term protection provided by the three adju-
vanted vaccines was compared. When challenged with a
lethal dose of SG-MCMV at 6 months post-immunization,
MF59-treated mice were protected, with a survival rate of
93% (13/14). The alum-adjuvanted group had a survival
rate of 86% (12/14). In comparison, chitosan had a less sat-
isfactory adjuvant effect, with a survival rate of 43% (6/14).
These results strongly suggest that immunization with
adjuvanted FI-MCMV vaccine elicits a stronger protective
immune response and can provide longer protection than
immunization with adjuvant-free vaccine. From the per-
spective of long-term protection, adjuvant MF59 had simi-
lar efficacy as Alum, both of which were slightly superior to
chitosan. However, all conferred significantly better protec-
tion than the adjuvant-free vaccine.
Protection against lethal SG-MCMV challenge in mice
immunized with FI-MCMV vaccine alone or adjuvanted
FI-MCMV by intramuscular injection
In the above-described experiments, the vaccine formu-
lation was applied intraperitoneally. To mimic real-life
settings, we also performed vaccinations by i.m. injec-
tion, which is a common route in vaccine adminis-
tration. Mice were immunized with various doses of
FI-MCMV intramuscularly with or without MF59, alum,
or chitosan as adjuvant. Meanwhile some other mice were
treated with PBS or the three adjuvants only (Table 4).
Figure 1 Bodyweight changes after virus challenge. Mice were
intraperitoneally immunized twice, at a 3-week interval, with 4 μg
(A), 1 μg (B), and 0.25 μg (C) of the vaccine with or without an
adjuvant (MF59, alum, or chitosan). Mice were challenged with a
lethal dose of SG-MCMV 3 weeks after the second immunization and
the body weights were measured from the time of the challenge to
3 weeks after the challenge. Data points represent mean ± SD.
aSignificant difference (p <0.05) vs the corresponding adjuvant-free
subjects. bp <0.05 vs the corresponding alum-adjuvant subjects.
cp <0.05 vs the corresponding chitosan-adjuvant subjects.
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Serum samples from the immunized mice were obtained
3 weeks after the first and second immunization and
used for IgG Ab assays. Three weeks after immunization,
all the mice were challenged with a lethal dose of
SG-MCMV.
As shown in Table 4, the FI-MCMV vaccine also effect-
ively induced a humoral immune response when given
intramuscularly. Antibody titers after the booster injection
were higher than those after priming. After immunization
with adjuvanted vaccines, antibody levels increased obvi-
ously compared with immunization with adjuvant-free vac-
cines. MF59-adjuvanted groups showed the best antibody
response. Antibody titers in the alum groups were close to
those in the chitosan groups. No anti-MCMV IgG was
detected in MF59-, alum-, or chitosan-only treated mice,
and these mice died within 1 week after lethal challenge.
Table 3 Long-term protection in mice immunized with inactivated vaccine with or without adjuvanta
Immunogen Dosage
(μg)
ELISA titer (2n) of IgG antibodyb
(6 months after the last immunization)
Protection against SGV challenge
Survival mice/total mice
Adjuvant-free 4 8.0 ± 0.8 3/14
+Chitosan 9.5 ± 1.0d 6/14c
+Alum 11.7 ± 0.5d 12/14c,d
+MF59 12.3 ± 0.6d 13/14c,d
PBS - - 1/15
aMice were immunized by i.p. injection twice, 3 weeks apart, with 4 μg of the inactivated vaccine with or without an adjuvant (MF59, alum, or chitosan). Mice
were challenged with a lethal dose of SG-MCMV 6 months after the last immunization. Serum samples from the immunized mice were collected 2 days prior to
challenge. The survival of mice 3 weeks after the challenge was measured.
bValues represent means ± SD of each group.
cSignificant difference (p < 0.05), compared with control.
dSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
Table 4 Antibody titers and protection against SG-MCMV challenge in mice immunized with various doses of FI-MCMV
with or without adjuvant by i.m. injectiona
Immunogen FI-MCMV ELISA titer (2n) of IgG antibodyb Protection against SG-MCMV challenge
Dosage (μg) Immunization once Immunization twice Spleen virus titers (log10 PFU/ml) Survival mice/tested mice
Adjuvant-free 0.25 3.67 ± 1.15 5.33 ± 0.58 5.27 ± 0.19 0/6
+ Chitosan 5.00 ± 1.00 9.67 ± 1.15c 5.08 ± 0.13 0/6
+ Alum 6.33 ± 1.53c 11.33 ± 1.15c 5.14 ± 0.11 0/6
+ MF59 7.33 ± 0.58c 12.33 ± 1.53c 4.58 ± 0.36c,e 2/6
Adjuvant-free 1 4.67 ± 1.15 10.00 ± 1.73 5.13 ± 0.29 0/6
+ Chitosan 6.33 ± 0.58 12.00 ± 1.00c 4.64 ± 0.50e 2/6
+ Alum 7.33 ± 0.58c 12.33 ± 1.15c 4.78 ± 0.15e 1/6
+ MF59 10.67 ± 1.15c,d 15.00 ± 1.00c,d 3.51 ± 0.49c,d,e 5/6e
Adjuvant-free 4 7.67 ± 0.58 11.67 ± 1.52 4.41 ± 0.48e 3/6
+ Chitosan 10.00 ± 1.73c 13.67 ± 0.58c 4.02 ± 0.51e 5/6e
+ Alum 10.33 ± 0.58c 14.00 ± 1.00c 3.80 ± 0.11c,e 6/6e
+ MF59 11.67 ± 0.58c 16.33 ± 0.58c,d 2.56 ± 0.77c,d,e 6/6e
Chitosan only - Undetected Undetected 5.87 ± 0.17 0/6
Alum only Undetected Undetected 5.68 ± 0.27 0/6
MF59 only Undetected Undetected 5.62 ± 0.38 0/6
Mock Undetected Undetected 5.73 ± 0.34 0/6
PBS - - 5.91 ± 0.39 0/6
aThe mice were immunized twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan) by i.m.
injection. Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Three weeks after immunization, all
the mice were challenged with a lethal dose of SG-MCMV. Spleen virus titers 5 days after challenge and survival rates of mice 21 days post-infection were
determined. Results are expressed as means ± SD of tested mice in each group.
bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
eSignificant difference (p < 0.05), compared with corresponding control subjects.
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Vaccination with FI-MCMV alone at all three doses did not
provide effective protection, but immunization with adju-
vanted FI-MCMV obviously improved protection. At the
4 μg dose only, full protection was observed in all three
adjuvanted groups by i.m. route. At the 1 μg dose, the sur-
vival rates in the adjuvanted FI-MCMV groups decreased
correspondingly. No effective protection was observed in
the mice immunized with adjuvanted vaccine at the low
0.25 μg dose. Vaccinated groups had lower virus titers in
the spleen than the control and adjuvant-only groups.
Addition of an adjuvant (MF59, alum, or chitosan) to
vaccines further reduced virus titers in the spleen. The most
remarkable difference was found in the MF59-adjuvanted
4 μg vaccine group, as its spleen virus titer was almost
103-fold lower than that of the control group (Table 4). This
i.m. immunization experiment also illustrated that adju-
vanted FI-MCMV vaccine induced better immune protec-
tion and MF59 showed a superior immune enhancement
effect relative to alum and chitosan.
Discussion
Several features of HCMV infection render the research
and development of a safe and effective CMV vaccine
quite difficult. CMV is able to evade the immune
response, and some HCMV genes modulate host innate
or adaptive immune responses to benefit survival of the
virus itself [24]. Studying the immune-evading mecha-
nisms of CMV is critical for the development of an
effective CMV vaccine [1]. In addition, the lifelong
latency and ability to re-infect, despite pre-existing
natural immunity, represent a significant safety concern
for the application of attenuated live vaccines [4,16].
CMV has strict species specificity, and therefore no
animal model exists that would allow the direct study
of the mechanisms of HCMV infection and the effects
of vaccine immunization [25]. All of the above factors
have restricted the progress of CMV vaccine develop-
ment. Despite many attempts, no CMV vaccine has
been approved for human use [4,10].
The essential components that constitute an effective
CMV vaccine are not yet clear [26,27]. There is increas-
ing awareness that the actual host immune responses
for HCMV infection are far more complex than was
previously imagined. Considering that the protective
effects for most CMV vaccine candidates in clinical
studies are unsatisfactory, the singular vaccine antigen
composition might be a key reason. Therefore, some
experts have pointed out that the immune responses
induced by a safe and effective CMV vaccine should
target multiple antigens expressed at different stages of
virus replication, and more importantly, vaccine effect-
iveness should not be impaired by the virus evading the
immune response [4]. Another important issue to con-
sider is the clinical settings of reinfection by different
CMV strains, a reminder that vaccine design should
aim for cross-protection against infection by multiple
epidemic CMV strains. Inactivated CMV vaccines with
whole virus particle proteins, especially those envelope
glycoproteins critical for immunity, are capable of indu-
cing more diverse immune responses, which might be
more similar to the host immune responses induced by
natural infections. In contrast, a subunit vaccine has a
singular antigenic component, and its limited antigen
epitopes could not exert the same role in inducing host
immune responses as multiple antigen epitopes of an
inactivated vaccine under near natural conditions.
Therefore, it is necessary to study the immunization
effects and strategies of inactivated CMV vaccines. For
the past 30 years researchers have studied the inacti-
vated MCMV vaccine in animal experiments. In 1980,
Tolpin et al. reported that two immunizations of mice
with inactivated MCMV vaccine could provide a pro-
tection rate of 89% against a low-level virus challenge.
However, most mice still developed mild or subclinical
infections after challenge [21]. In 1996, Geoffroy et al. dem-
onstrated that the protective rate of an MCMV vaccine
inactivated by sodium periodate or β-propiolactone reached
100%, but the long-lasting protection offered was incom-
plete [22]. In 2002, Morello et al. proved that FI-MCMV
adjuvanted with alum induced effective protection; how-
ever, they only performed a sub-lethal challenge (<1 ×
LD50) [3]. Therefore, development of an inactivated vaccine
that could provide protection against lethal challenge and
long-term immunity remains to be a difficult task.
In addition to vaccines, adjuvant and delivery proto-
cols must be optimized. Co-administering vaccine with
a suitable adjuvant could significantly enhance the
immune response. These observations have prompted
searches for novel, safe, and effective adjuvants [28].
Many studies have reported that adjuvants may en-
hance the immunogenicity of inactivated or subunit
vaccines, such as those for influenza or HIV [29-31].
Here, we sought to immunize mice with an inactivated
CMV vaccine and several different adjuvants to test the
effects of adjuvant enhancement.
Our results illustrated that inactivated CMV vaccine
demonstrated good immunogenicity. Primary and booster
immunizations of 4 μg vaccine plus any of the three adju-
vants provided full protection. In particular, the MF59 adju-
vant, even at a low dose of 0.25 μg by i.p. injection,
conferred excellent protection against lethal challenge for
the mice. These results illustrated that vaccine plus adju-
vant could provide better protection, allowing for a reduc-
tion in the number of immunizations and sparing the
antigen dose. When the vaccine was given intramuscularly,
which is the most common route used to administer adju-
vanted vaccines in real-life settings, the results were similar
to those obtained by i.p. injection, whereas the overall
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protective efficacy of vaccine administered intramuscularly
was slightly inferior to that administered intraperitoneally.
The minimum vaccine dose of FI-MCMV for conferring
complete protection for the mice was higher for an i.m.
immunization than that for an i.p. immunization.
When the three types of adjuvants are compared
for immune enhancement, MF59 is the most effective,
and chitosan has equivalent activities as alum. The
mechanisms by which these three adjuvants work are
not clear [32]. Alum adjuvant may granulate antigens
and activate the innate immune pathway, creating an
active immune environment at the injection site, and
thus promoting the co-immunized antigen to induce
an antibody response [17,33,34]. Adjuvant MF59 is a
type of oil-in-water emulsion, in which the oil drops
consist of metabolizable squalene and the emulsifying
agent is a mixture of Tween 80 and Span 85. Animal
experiments have demonstrated that MF59 differs
from alum in that it does not prolong antigen pres-
ence at the injection site, indicating that MF59 does
not exert its adjuvant effect through the “depot-effect” [31].
Studies have shown that at least three human cells are
targets of MF59, including monocytes, macrophages, and
granulocytes. MF59 induces monocytes to differentiate
towards dendritic cells by up-regulating the co-stimulatory
molecule CD86 and down-regulating the monocyte marker
CD14. MF59 induces a series of in vivo effects, such as pro-
moting antigen uptake, chemokine release, and cell differ-
entiation, and significantly promotes a strong immune
response to co-administered antigens by inducing a local
inflammatory environment at the injection site [17,35,36].
Chitosan is a safe, non-toxic, natural cationic polymer. Its
advantages include a relatively low price, good tolerability,
auto-degradability, and high viscosity, which have made it
an ideal adjuvant candidate. Chitosan can adsorb to nega-
tively charged substances, such as cell membranes and
mucosa surfaces, and can prolong the half-life of antigens
on the mucosal surface. In addition, chitosan can stimulate
macrophages and natural killer cells and therefore promote
immune responses [37]. Both MF59 and chitosan are
considered to have excellent prospects as adjuvants.
There is increasing evidence that a reduction in
viral load provides significant therapeutic benefits to
patients suffering from HCMV disease, and that
CMV vaccination is the most practical approach for
realizing this goal [38]. In our experiments, the viral
loads in both spleen and salivary glands for immu-
nized mice were significantly lower than those for
the control mice. For example, the virus titer in the
spleen of the MF59-adjuvanted group (4 μg) was
more than 103-fold lower than that of the control
group, indicating that immunity induced by inacti-
vated vaccine could effectively eradicate infected
viruses in vivo. The reduction of viral load in target
organs such as the salivary glands and spleen is an
important indicator for demonstrating the protective
effects of a CMV vaccine.
As CMV vaccines currently in development do not
prevent viral infection, several scholars have suggested
that a more realistic goal for CMV vaccines should be
to limit or prevent HCMV disease rather than to en-
tirely prevent infection [4,38]. Our study supports this
perspective. Although immunization with an inacti-
vated vaccine, in particular with adjuvants, elicited a
robust immune response and results in significantly
lower virus titers in infected organs compared with
controls, it could not achieve complete viral clearance
in vivo. We found only one instance of virus being
undetectable (in a mouse salivary gland in the MF59-
adjuvanted group). Certainly, we need to consider that
the virus used for challenge had enhanced virulence
via serial passage of SG homogenates and was much
more virulent than wild-type virus. The challenge
method used was a lethal high-dose infection, and
thus the experimental challenge was far more hazard-
ous than would occur naturally. Therefore, it is en-
tirely possible that an inactivated CMV vaccine could
elicit better immune protection against naturally oc-
curring common CMV infections.
Some studies have highlighted that the duration of
protective immunity induced by CMV vaccines is also
an important factor in vaccine development [4]. People
are mostly interested in a vaccine that can prevent
congenital infection or disease, and has the capacity to
maintain long-term immunity, lasting for several years.
One method of inducing long-term immunity is to
adopt multiple regular boosts, but the shortcoming of
such a method is increased cost. Alternatively, adjuvant
can be used to enhance immune responses to achieve
satisfactory immune protection.
Conclusions
Our study demonstrates that inactivated CMV vaccine
has good immunogenicity and is a feasible candidate for
preventing CMV infection. Co-administration of the
vaccine with adjuvant significantly improves the efficacy
of the inactivated vaccine and enhances the immune
response in mice. More importantly, immunization with
adjuvanted vaccine may provide more effective and
longer-term protection than adjuvant-free vaccines.
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